Journal of Enzyme Inhibition and Medicinal Chemistry (Dec 2022)

Identification of novel pyrrolopyrimidine and pyrrolopyridine derivatives as potent ENPP1 inhibitors

  • Hee Jin Jeong,
  • Hye Lim Lee,
  • Sung Joon Kim,
  • Jeong Hyun Jeong,
  • Su Hyun Ji,
  • Han Byeol Kim,
  • Miso Kang,
  • Hwan Won Chung,
  • Chan Sun Park,
  • Hyunah Choo,
  • Hyo Jae Yoon,
  • Nam-Jung Kim,
  • Duck-Hyung Lee,
  • Sanghee Lee,
  • Seo-Jung Han

DOI
https://doi.org/10.1080/14756366.2022.2119566
Journal volume & issue
Vol. 37, no. 1
pp. 2434 – 2451

Abstract

Read online

In an effort to discover novel scaffolds of non-nucleotide-derived Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitors to stimulate the Stimulator of Interferon Genes (STING) pathway, we designed and synthesised pyrrolopyrimidine and pyrrolopyridine derivatives and performed structure-activity relationship (SAR) study. We found 18p possessed high potency (IC50 = 25.0 nM) against ENPP1, and activated STING pathway in a concentration dependent manner. Also, in response to STING pathway activation, cytokines such as IFN-β and IP-10 were induced by 18p in a concentration dependent manner. Finally, we discovered that 18p causes inhibition of tumour growth in 4T1 syngeneic mouse model. This study provides new insight into the designing of novel ENPP1 inhibitors and warrants further development of small molecule immune modulators for cancer immunotherapy.

Keywords